Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Londo who wrote (2407)	12/29/2000 4:25:07 PM
From: Scott H. Davis	Read Replies (3) \| Respond to of 52153

Londo & all: Would it be worthwhile to compile a list of biotechs with a healthy supply of cash that also have years of it remaining a present burn rates, to see how they have fared a year from now vs a biotech index? Intangibles could also be noted, such as how well present management has used funding. I certainly don't know a lot of biotechs well, but I do know VICL fits will in terms of having many years of funding & using funds well. From their last qtr, they had $150.4m cash & securities, and for the 9 months, used up $5.6m. MLNM had $679m cash & securities, burned thru 70m for 9 months, and had a $704m public offering in Oct (don't know how much sold) ABGX had $761m (qtr + 230m private - 9m acquisition) but only burned $4.4 m for the 9 months. For MLNM & ABGX, I can't comment on historical cash use, as I have not followed them as long or as in depth as VICL. Any other candidates? Any interest? worth a 1 year thread? Scott